Ty Kiser
Concepts (447)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 13 | 2022 | 729 | 2.520 |
Why?
| | Venous Thromboembolism | 6 | 2025 | 326 | 2.420 |
Why?
| | Teicoplanin | 3 | 2024 | 14 | 2.140 |
Why?
| | Anti-Bacterial Agents | 15 | 2024 | 1928 | 2.090 |
Why?
| | Heparin | 10 | 2019 | 243 | 1.930 |
Why?
| | Vancomycin | 6 | 2024 | 94 | 1.820 |
Why?
| | Thrombocytopenia | 9 | 2020 | 202 | 1.790 |
Why?
| | Hirudins | 8 | 2020 | 51 | 1.740 |
Why?
| | Critical Illness | 21 | 2025 | 888 | 1.710 |
Why?
| | Factor Xa Inhibitors | 3 | 2025 | 187 | 1.680 |
Why?
| | Voriconazole | 3 | 2019 | 21 | 1.540 |
Why?
| | Intensive Care Units | 22 | 2025 | 915 | 1.500 |
Why?
| | Peptide Fragments | 7 | 2020 | 691 | 1.470 |
Why?
| | Triazoles | 3 | 2019 | 184 | 1.390 |
Why?
| | Antithrombins | 4 | 2020 | 69 | 1.390 |
Why?
| | Peritonitis | 2 | 2024 | 83 | 1.380 |
Why?
| | Antifungal Agents | 5 | 2025 | 150 | 1.320 |
Why?
| | Peritoneal Dialysis | 2 | 2024 | 99 | 1.290 |
Why?
| | Hemofiltration | 4 | 2017 | 24 | 1.240 |
Why?
| | Drug Packaging | 3 | 2016 | 41 | 1.200 |
Why?
| | Thrombin | 3 | 2020 | 167 | 1.180 |
Why?
| | Thrombosis | 4 | 2021 | 396 | 1.150 |
Why?
| | Drug Compounding | 3 | 2026 | 107 | 1.140 |
Why?
| | Pipecolic Acids | 4 | 2020 | 24 | 1.040 |
Why?
| | Thromboembolism | 3 | 2021 | 126 | 1.030 |
Why?
| | Critical Care | 11 | 2024 | 695 | 1.030 |
Why?
| | Fibrinolytic Agents | 4 | 2018 | 290 | 1.010 |
Why?
| | Hypnotics and Sedatives | 7 | 2025 | 216 | 1.000 |
Why?
| | Rivaroxaban | 3 | 2025 | 268 | 0.980 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.980 |
Why?
| | Invasive Fungal Infections | 3 | 2025 | 11 | 0.980 |
Why?
| | Microbial Sensitivity Tests | 6 | 2021 | 373 | 0.980 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 241 | 0.970 |
Why?
| | Thiamine | 1 | 2026 | 18 | 0.950 |
Why?
| | Hospitalization | 9 | 2025 | 2446 | 0.940 |
Why?
| | Middle Aged | 56 | 2026 | 35971 | 0.920 |
Why?
| | Pharmacists | 5 | 2024 | 240 | 0.900 |
Why?
| | Kidney Diseases | 5 | 2021 | 427 | 0.890 |
Why?
| | beta-Cyclodextrins | 2 | 2015 | 32 | 0.890 |
Why?
| | Retrospective Studies | 39 | 2026 | 17149 | 0.850 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 919 | 0.840 |
Why?
| | Aged | 41 | 2026 | 25955 | 0.840 |
Why?
| | Pharmacy Service, Hospital | 2 | 2024 | 81 | 0.810 |
Why?
| | Syringes | 3 | 2016 | 49 | 0.790 |
Why?
| | Humans | 100 | 2026 | 144667 | 0.780 |
Why?
| | Renal Replacement Therapy | 4 | 2022 | 99 | 0.770 |
Why?
| | Professional Role | 1 | 2024 | 159 | 0.770 |
Why?
| | Factor Xa | 2 | 2021 | 34 | 0.740 |
Why?
| | Hospital Mortality | 7 | 2025 | 1033 | 0.730 |
Why?
| | Dalteparin | 2 | 2020 | 10 | 0.720 |
Why?
| | Drug Stability | 4 | 2016 | 169 | 0.710 |
Why?
| | Nephrologists | 1 | 2021 | 14 | 0.690 |
Why?
| | Partial Thromboplastin Time | 5 | 2014 | 52 | 0.690 |
Why?
| | Recombinant Proteins | 10 | 2021 | 1363 | 0.680 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2020 | 70 | 0.680 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 480 | 0.680 |
Why?
| | Infusions, Intravenous | 7 | 2026 | 422 | 0.680 |
Why?
| | Adult | 42 | 2025 | 40489 | 0.670 |
Why?
| | Male | 59 | 2026 | 72431 | 0.670 |
Why?
| | Female | 59 | 2026 | 78304 | 0.670 |
Why?
| | Blood Coagulation Tests | 3 | 2016 | 69 | 0.640 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2019 | 2019 | 0.620 |
Why?
| | Gram-Positive Bacteria | 1 | 2020 | 49 | 0.620 |
Why?
| | Pseudomonas Infections | 2 | 2013 | 230 | 0.610 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 19 | 0.600 |
Why?
| | Drug Monitoring | 4 | 2017 | 396 | 0.600 |
Why?
| | Kidney Failure, Chronic | 3 | 2020 | 597 | 0.590 |
Why?
| | Antiviral Agents | 3 | 2020 | 765 | 0.580 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 555 | 0.570 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 201 | 0.570 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 36 | 0.570 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.560 |
Why?
| | Diabetic Ketoacidosis | 1 | 2021 | 210 | 0.550 |
Why?
| | Dexmedetomidine | 4 | 2014 | 44 | 0.550 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 82 | 0.540 |
Why?
| | Obesity, Morbid | 1 | 2022 | 288 | 0.540 |
Why?
| | Cold Temperature | 2 | 2016 | 208 | 0.540 |
Why?
| | Nitriles | 1 | 2019 | 205 | 0.530 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 15 | 0.520 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 764 | 0.520 |
Why?
| | Ribavirin | 2 | 2020 | 80 | 0.510 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.510 |
Why?
| | Anticonvulsants | 2 | 2017 | 242 | 0.510 |
Why?
| | Hemorrhage | 6 | 2022 | 813 | 0.500 |
Why?
| | Blood Transfusion | 2 | 2020 | 405 | 0.500 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8284 | 0.500 |
Why?
| | Academic Medical Centers | 4 | 2026 | 545 | 0.500 |
Why?
| | Treatment Outcome | 20 | 2025 | 11735 | 0.490 |
Why?
| | Glass | 1 | 2016 | 47 | 0.490 |
Why?
| | Lung Transplantation | 3 | 2020 | 329 | 0.480 |
Why?
| | Nitroprusside | 1 | 2016 | 71 | 0.480 |
Why?
| | Thiocyanates | 1 | 2016 | 27 | 0.480 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.480 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 101 | 0.480 |
Why?
| | Freezing | 1 | 2016 | 86 | 0.470 |
Why?
| | Cyclodextrins | 1 | 2015 | 11 | 0.460 |
Why?
| | Cerebral Hemorrhage | 1 | 2016 | 120 | 0.440 |
Why?
| | Vasodilator Agents | 2 | 2016 | 329 | 0.440 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.440 |
Why?
| | Cardiopulmonary Bypass | 2 | 2016 | 217 | 0.440 |
Why?
| | Neoplasms | 3 | 2020 | 2873 | 0.430 |
Why?
| | Curriculum | 2 | 2021 | 1063 | 0.430 |
Why?
| | Pyridines | 1 | 2019 | 603 | 0.420 |
Why?
| | Antidotes | 1 | 2016 | 145 | 0.420 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 324 | 0.420 |
Why?
| | Vasoconstriction | 2 | 2023 | 216 | 0.410 |
Why?
| | Kidney | 2 | 2021 | 1495 | 0.410 |
Why?
| | Methylprednisolone | 1 | 2014 | 58 | 0.410 |
Why?
| | Osmotic Pressure | 1 | 2014 | 41 | 0.410 |
Why?
| | Stroke | 2 | 2022 | 1262 | 0.400 |
Why?
| | Cohort Studies | 14 | 2021 | 5957 | 0.390 |
Why?
| | Patient Admission | 2 | 2025 | 220 | 0.390 |
Why?
| | Dronabinol | 1 | 2016 | 249 | 0.390 |
Why?
| | Arginine | 4 | 2020 | 238 | 0.360 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1537 | 0.360 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.360 |
Why?
| | Ganciclovir | 1 | 2012 | 53 | 0.360 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 438 | 0.350 |
Why?
| | Benzodiazepines | 3 | 2025 | 168 | 0.350 |
Why?
| | Administration, Oral | 4 | 2022 | 851 | 0.340 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.340 |
Why?
| | Prospective Studies | 9 | 2025 | 7994 | 0.340 |
Why?
| | Pharmacies | 2 | 2021 | 40 | 0.330 |
Why?
| | Pharmacy | 2 | 2021 | 30 | 0.330 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.330 |
Why?
| | Pseudomonas aeruginosa | 2 | 2013 | 391 | 0.330 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2022 | 187 | 0.330 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.320 |
Why?
| | Nomograms | 1 | 2011 | 59 | 0.320 |
Why?
| | Acute Kidney Injury | 4 | 2018 | 869 | 0.310 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 205 | 0.310 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 202 | 0.300 |
Why?
| | Midazolam | 2 | 2024 | 72 | 0.300 |
Why?
| | Sulfonamides | 4 | 2020 | 579 | 0.300 |
Why?
| | Neuromuscular Blockade | 2 | 2025 | 51 | 0.300 |
Why?
| | Time Factors | 7 | 2018 | 7140 | 0.290 |
Why?
| | Drug Therapy, Combination | 5 | 2021 | 1044 | 0.280 |
Why?
| | Propofol | 2 | 2025 | 85 | 0.270 |
Why?
| | Students, Pharmacy | 2 | 2021 | 95 | 0.270 |
Why?
| | Young Adult | 9 | 2025 | 14122 | 0.270 |
Why?
| | Thrombin Time | 2 | 2020 | 11 | 0.260 |
Why?
| | Burns | 2 | 2018 | 371 | 0.260 |
Why?
| | Daptomycin | 2 | 2021 | 18 | 0.260 |
Why?
| | Sympathomimetics | 1 | 2007 | 19 | 0.260 |
Why?
| | Polypropylenes | 1 | 2007 | 12 | 0.260 |
Why?
| | Phenylephrine | 1 | 2007 | 74 | 0.260 |
Why?
| | Expectorants | 1 | 2007 | 23 | 0.260 |
Why?
| | Administration, Intravenous | 3 | 2017 | 170 | 0.250 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.250 |
Why?
| | Patient Discharge | 3 | 2018 | 985 | 0.250 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 22 | 0.250 |
Why?
| | Drug Storage | 3 | 2016 | 53 | 0.250 |
Why?
| | Lorazepam | 3 | 2014 | 25 | 0.240 |
Why?
| | Ofloxacin | 1 | 2006 | 17 | 0.240 |
Why?
| | Levofloxacin | 1 | 2006 | 20 | 0.240 |
Why?
| | Acetylcysteine | 1 | 2007 | 136 | 0.240 |
Why?
| | Respiration | 1 | 2007 | 206 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1090 | 0.230 |
Why?
| | Gentamicins | 2 | 2023 | 50 | 0.230 |
Why?
| | Anesthetics | 1 | 2007 | 99 | 0.230 |
Why?
| | Alcoholism | 2 | 2023 | 813 | 0.230 |
Why?
| | Adolescent | 10 | 2025 | 22409 | 0.230 |
Why?
| | Models, Biological | 1 | 2013 | 1811 | 0.230 |
Why?
| | Area Under Curve | 4 | 2019 | 329 | 0.230 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.220 |
Why?
| | Vasoconstrictor Agents | 2 | 2023 | 144 | 0.220 |
Why?
| | Octreotide | 1 | 2005 | 23 | 0.220 |
Why?
| | Costs and Cost Analysis | 1 | 2026 | 221 | 0.220 |
Why?
| | Pneumonia | 3 | 2023 | 629 | 0.220 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2018 | 26 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3910 | 0.210 |
Why?
| | Cross-Over Studies | 2 | 2020 | 605 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2024 | 580 | 0.200 |
Why?
| | Warfarin | 2 | 2022 | 173 | 0.200 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2016 | 562 | 0.200 |
Why?
| | Length of Stay | 4 | 2019 | 1339 | 0.200 |
Why?
| | Temperature | 3 | 2016 | 680 | 0.200 |
Why?
| | Blood Coagulation | 2 | 2016 | 268 | 0.190 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 43 | 0.190 |
Why?
| | Liver Diseases | 1 | 2006 | 304 | 0.190 |
Why?
| | Ethanol | 3 | 2022 | 627 | 0.180 |
Why?
| | Incidence | 2 | 2020 | 2892 | 0.180 |
Why?
| | Liver Transplantation | 1 | 2009 | 826 | 0.180 |
Why?
| | Risk Factors | 7 | 2023 | 10796 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1360 | 0.180 |
Why?
| | Thinness | 1 | 2022 | 98 | 0.170 |
Why?
| | Sexual Harassment | 1 | 2021 | 28 | 0.170 |
Why?
| | Aspergillosis | 1 | 2021 | 24 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 24 | 0.170 |
Why?
| | Statistics, Nonparametric | 3 | 2017 | 427 | 0.170 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 76 | 0.170 |
Why?
| | Candidiasis | 1 | 2021 | 64 | 0.170 |
Why?
| | Community Pharmacy Services | 1 | 2021 | 46 | 0.160 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 779 | 0.160 |
Why?
| | Cephalosporins | 1 | 2021 | 47 | 0.160 |
Why?
| | United States | 10 | 2025 | 16018 | 0.160 |
Why?
| | Ascitic Fluid | 1 | 2020 | 15 | 0.160 |
Why?
| | Vasoplegia | 1 | 2020 | 5 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2021 | 164 | 0.150 |
Why?
| | Platelet Count | 1 | 2020 | 94 | 0.150 |
Why?
| | Asthma | 2 | 2022 | 1774 | 0.150 |
Why?
| | Monte Carlo Method | 2 | 2013 | 153 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1142 | 0.150 |
Why?
| | Hydroxocobalamin | 1 | 2020 | 33 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 242 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Body Weight | 2 | 2021 | 968 | 0.150 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2020 | 138 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 565 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Hemostasis | 1 | 2019 | 98 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Gastric Emptying | 2 | 2008 | 36 | 0.140 |
Why?
| | Calcineurin Inhibitors | 1 | 2018 | 69 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 134 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 47 | 0.130 |
Why?
| | Logistic Models | 3 | 2017 | 2114 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 387 | 0.130 |
Why?
| | Kidney Transplantation | 2 | 2018 | 709 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 248 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 323 | 0.130 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 167 | 0.130 |
Why?
| | Gastrointestinal Agents | 2 | 2008 | 65 | 0.130 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 12 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 146 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 109 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2018 | 120 | 0.130 |
Why?
| | Self-Directed Learning as Topic | 1 | 2017 | 5 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 129 | 0.130 |
Why?
| | Pharmaceutical Solutions | 1 | 2016 | 14 | 0.120 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2016 | 27 | 0.120 |
Why?
| | Career Mobility | 1 | 2017 | 70 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 768 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 388 | 0.120 |
Why?
| | Capsules | 1 | 2016 | 42 | 0.120 |
Why?
| | Transplant Recipients | 2 | 2018 | 180 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 662 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 236 | 0.120 |
Why?
| | Patient Readmission | 2 | 2019 | 765 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 373 | 0.120 |
Why?
| | Regression Analysis | 2 | 2016 | 998 | 0.120 |
Why?
| | Databases, Factual | 2 | 2019 | 1494 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2015 | 5 | 0.120 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 77 | 0.120 |
Why?
| | Enteral Nutrition | 2 | 2008 | 217 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 283 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 334 | 0.110 |
Why?
| | Calibration | 1 | 2016 | 151 | 0.110 |
Why?
| | Pharmacokinetics | 1 | 2015 | 32 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2019 | 287 | 0.110 |
Why?
| | Isoxazoles | 1 | 2015 | 52 | 0.110 |
Why?
| | Societies, Pharmaceutical | 1 | 2015 | 14 | 0.110 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 10 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 338 | 0.110 |
Why?
| | Administration, Inhalation | 1 | 2016 | 570 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 536 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 990 | 0.110 |
Why?
| | Respiration, Artificial | 4 | 2025 | 710 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.110 |
Why?
| | Anti-Ulcer Agents | 1 | 2014 | 12 | 0.110 |
Why?
| | Histamine H2 Antagonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Prosthesis-Related Infections | 1 | 2015 | 98 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 601 | 0.110 |
Why?
| | Peptic Ulcer | 1 | 2014 | 18 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2014 | 2033 | 0.110 |
Why?
| | Diltiazem | 1 | 2014 | 17 | 0.100 |
Why?
| | Teaching | 1 | 2017 | 237 | 0.100 |
Why?
| | Dabigatran | 1 | 2014 | 29 | 0.100 |
Why?
| | Thromboplastin | 1 | 2014 | 64 | 0.100 |
Why?
| | beta-Alanine | 1 | 2014 | 24 | 0.100 |
Why?
| | Pyridones | 1 | 2016 | 201 | 0.100 |
Why?
| | Drug Dosage Calculations | 1 | 2014 | 27 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2018 | 886 | 0.100 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 109 | 0.100 |
Why?
| | Medication Adherence | 1 | 2018 | 540 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 267 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2014 | 136 | 0.100 |
Why?
| | Oxazolidinones | 1 | 2012 | 17 | 0.090 |
Why?
| | Seizures | 1 | 2017 | 477 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2014 | 187 | 0.090 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 304 | 0.090 |
Why?
| | APACHE | 2 | 2010 | 66 | 0.090 |
Why?
| | Acetamides | 1 | 2012 | 38 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 134 | 0.090 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 175 | 0.090 |
Why?
| | Learning | 1 | 2017 | 448 | 0.090 |
Why?
| | Motivation | 1 | 2017 | 601 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 280 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 881 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 365 | 0.090 |
Why?
| | Colorado | 3 | 2017 | 4558 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1029 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 727 | 0.090 |
Why?
| | Pyrazoles | 1 | 2016 | 512 | 0.090 |
Why?
| | Mental Recall | 1 | 2013 | 222 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 198 | 0.090 |
Why?
| | Metoclopramide | 2 | 2008 | 19 | 0.090 |
Why?
| | Coronary Artery Bypass | 1 | 2014 | 267 | 0.090 |
Why?
| | Erythromycin | 2 | 2008 | 19 | 0.090 |
Why?
| | Research | 1 | 2015 | 431 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 613 | 0.080 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 197 | 0.080 |
Why?
| | Disease Progression | 2 | 2020 | 2847 | 0.080 |
Why?
| | Lipids | 1 | 2016 | 706 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2015 | 355 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 528 | 0.080 |
Why?
| | Aortic Valve | 1 | 2014 | 364 | 0.080 |
Why?
| | Imipenem | 1 | 2010 | 16 | 0.080 |
Why?
| | Genes, Regulator | 1 | 2010 | 35 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 477 | 0.080 |
Why?
| | Drug Resistance | 1 | 2011 | 145 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 330 | 0.080 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.080 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 324 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 94 | 0.080 |
Why?
| | Protein C | 1 | 2010 | 53 | 0.080 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.070 |
Why?
| | Risk Assessment | 2 | 2016 | 3729 | 0.070 |
Why?
| | Biomedical Research | 1 | 2015 | 712 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2010 | 288 | 0.070 |
Why?
| | Acetaminophen | 2 | 2008 | 265 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1995 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2839 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 156 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1938 | 0.070 |
Why?
| | Certification | 1 | 2009 | 118 | 0.070 |
Why?
| | Standard of Care | 2 | 2021 | 81 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 4261 | 0.060 |
Why?
| | Lung Diseases | 1 | 2014 | 781 | 0.060 |
Why?
| | Cost Control | 1 | 2007 | 37 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 287 | 0.060 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2019 | 6399 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 509 | 0.060 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 125 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2010 | 465 | 0.060 |
Why?
| | Half-Life | 1 | 2006 | 152 | 0.060 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 48 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2325 | 0.060 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 5 | 0.060 |
Why?
| | Fentanyl | 1 | 2007 | 127 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2005 | 98 | 0.060 |
Why?
| | Platelet Activation | 1 | 2005 | 98 | 0.060 |
Why?
| | Chromatography, Liquid | 1 | 2007 | 444 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2922 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2591 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1569 | 0.050 |
Why?
| | DNA | 1 | 2010 | 1447 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.050 |
Why?
| | Penicillins | 1 | 2023 | 61 | 0.050 |
Why?
| | Animals | 2 | 2016 | 37948 | 0.050 |
Why?
| | Transcription Factors | 1 | 2010 | 1726 | 0.040 |
Why?
| | Minnesota | 1 | 2022 | 170 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 1021 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.040 |
Why?
| | Serum Albumin | 1 | 2022 | 144 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Gender Identity | 1 | 2021 | 126 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 82 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 45 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 259 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1948 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 657 | 0.040 |
Why?
| | Hypersensitivity | 1 | 2023 | 253 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 352 | 0.040 |
Why?
| | Methylene Blue | 1 | 2020 | 24 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 6041 | 0.040 |
Why?
| | Sepsis | 2 | 2020 | 643 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 4081 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 275 | 0.040 |
Why?
| | Pilot Projects | 2 | 2015 | 1886 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2020 | 368 | 0.030 |
Why?
| | Bacteremia | 1 | 2021 | 222 | 0.030 |
Why?
| | Sex Factors | 2 | 2018 | 2104 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 50 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 630 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 707 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 143 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 426 | 0.030 |
Why?
| | Drug Interactions | 1 | 2018 | 401 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 193 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2018 | 243 | 0.030 |
Why?
| | Problem-Based Learning | 1 | 2017 | 97 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1652 | 0.030 |
Why?
| | Pharmacology, Clinical | 1 | 2015 | 9 | 0.030 |
Why?
| | Risk | 1 | 2018 | 911 | 0.030 |
Why?
| | Expert Testimony | 1 | 2015 | 42 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 119 | 0.030 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 5 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 14 | 0.030 |
Why?
| | Checklist | 1 | 2015 | 111 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 41 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 47 | 0.030 |
Why?
| | Bradycardia | 1 | 2014 | 61 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 45 | 0.030 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.030 |
Why?
| | Everolimus | 1 | 2014 | 112 | 0.020 |
Why?
| | Educational Measurement | 1 | 2017 | 325 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 126 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2014 | 335 | 0.020 |
Why?
| | Delphi Technique | 1 | 2015 | 330 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 93 | 0.020 |
Why?
| | Demography | 1 | 2014 | 287 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 427 | 0.020 |
Why?
| | Cerebral Ventriculitis | 1 | 2012 | 3 | 0.020 |
Why?
| | Vancomycin Resistance | 1 | 2012 | 16 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 2012 | 58 | 0.020 |
Why?
| | Linezolid | 1 | 2012 | 25 | 0.020 |
Why?
| | Enterococcus faecium | 1 | 2012 | 22 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 537 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5870 | 0.020 |
Why?
| | Drainage | 1 | 2012 | 184 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 451 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 736 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 834 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 119 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1847 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 355 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3183 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2010 | 177 | 0.020 |
Why?
| | Specialization | 1 | 2009 | 136 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 25 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 368 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2008 | 81 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1056 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3603 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1180 | 0.010 |
Why?
| | Anxiety | 1 | 2013 | 1122 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4312 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5414 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2117 | 0.010 |
Why?
| | Depression | 1 | 2013 | 1561 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3329 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3414 | 0.010 |
Why?
| | Physicians | 1 | 2010 | 949 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1237 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|